We Claim:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

Ring Q is $(C_6\text{-}C_{10})$aryl or (4-10)-membered heterocyclyl;

R^1 is H, halo, $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$alkoxy, CN, CF_3, $-O\text{-}CF_3$, $-O\text{-}SO_2\text{-}(C_1\text{-}C_8)$alkyl, $-O\text{-}SO_2\text{-}(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl, $-(CR^{11}R^{12})_t(C_3\text{-}C_{10})$cycloalkyl-$(CR^{11}R^{12})_t$, $-(CR^{11}R^{12})_t(C_3\text{-}C_{10})$cycloalkyl-$(CR^{11}R^{12})_t$-O-, $-(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl-$(CR^{11}R^{12})_t$, $-(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl-$(CR^{11}R^{12})_t$-O-, $-(CR^{11}R^{12})_t$-(4-10)-membered heterocyclyl-$(CR^{11}R^{12})_t$, or $-(CR^{11}R^{12})_t$-(4-10)-membered heterocyclyl-$(CR^{11}R^{12})_t$-O-; wherein the ring carbon atoms of R^1 are optionally substituted by 1 to 3 R^{13} groups; and the ring nitrogen atoms of R^1 are optionally substituted by 1 to 3 $(C_1\text{-}C_8)$alkyl;

R^2 is H, $(C_1\text{-}C_8)$alkyl, $-(CR^{11}R^{12})_t\text{-}(C_3\text{-}C_{10})$cycloalkyl, $-(CR^{11}R^{12})_t\text{-}(C_6\text{-}C_{10})$aryl, or $-(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl; and wherein the carbon atoms of R^2 are optionally substituted by 1 to 3 R^{13} groups; and the ring nitrogen atoms of R^2 are optionally substituted by 1 to 3 $(C_1\text{-}C_8)$alkyl;

R^3 is selected from the group consisting of:

A)  ;

B)  ;

C)  ; and

D)  ;

Y is -(C=O)- or $-SO_2$-;

Y" is NR^{10} or –O-;

p is 0, 1, or 2;

each q, r, and t are independently 0, 1, 2, 3, 4, or 5;

each n is independently 0, 1, 2, 3, or 4;

each k is independently 1, 2, or 3;

each m and s are independently 0, 1, 2, or 3;

each j is 0, 1, or 2;

Each R^4 is $–(CR^{11}R^{12})_n$-, $-(CR^{11}R^{12})_n$-S-$(CR^{11}R^{12})_n$-, $–(CR^{11}R^{12})_n$-NR^{10}-, $-(CR^{11}R^{12})_n$-NR^{10}-$(CR^{11}R^{12})_n$-O-, $-(CR^{11}R^{12})_n$-O-$(CR^{11}R^{12})_k$-NR^{10}-, $-(CR^{11}R^{12})_n$-O-$(CR^{11}R^{12})_n$-, $-(CR^{11}R^{12})_n$-O-$(CR^{11}R^{12})_k$-O-$(CR^{11}R^{12})_n$-, $-(CR^{11}R^{12})_n$-CR^{11}=CR^{12}-$(CR^{11}R^{12})_n$-, or -CH=CH-$(CR^{11}R^{12})$-O-$(CH_2)_n$-;

Each R^5 is a bond or $–(CR^{11}R^{12})_m$-Z-$(CR^{11}R^{12})_s$; wherein Z is $-CR^{11}R^{12}$-, -O-, $-NR^{10a}$-, or $-S(O)_j$-;

Each R^6 is -(C=O)-OH, –(C=O)-OM^+, -(C=O)-$(C_1$-$C_8)$alkyl, -(C=O)-O-$(C_1$-$C_8)$alkyl, -(C=O)-$NR^{10}R^{11}$, -(C=O)-NR^{10}-SO_2-R^{11}, -SO_2-NH-R^{10}, -NH-SO_2-R^{10}, -(C=O)-NH-C≡N, or R^6 has a formula:



; or



;

M^+ is an alkali metal cation or an alkaline earth metal cation;

Each R^7 and R^8 is independently H, $(C_1$-$C_8)$alkyl, $(C_1$-$C_8)$alkoxy, $-(CR^{11}R^{12})_t(C_3$-$C_{10})$cycloalkyl, $-(CR^{11}R^{12})_t(C_6$-$C_{10})$aryl, $-(CR^{11}R^{12})_t(C_6$-$C_{10})$aryl-O-, $-(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl or $-(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl-O-;

Or R^7 and R^8 may optionally be taken together with the carbon to which they are attached to form a $(C_3$-$C_{10})$cycloalkyl or a (3-10)-membered heterocyclyl;

Each of Ar^1, Ar^2, Ar^3, and Ar^4 represents $(C_6$-$C_{10})$aryl or (5-10)-membered heterocyclyl; wherein the ring carbon atoms of each of Ar^1, Ar^2, Ar^3, and Ar^4 are optionally substituted by 1 to 3 R^{13} groups;

Ring A represents a 3, 4, 5, 6 or 7-membered ring optionally containing 1 to 4 heteroatoms which may be the same or different and which are selected from $-N(R^{10a})$-, O, and $S(O)_j$, wherein j is 0, 1, or 2, with the proviso that the ring does not contain two adjacent O or $S(O)_j$ atoms, and wherein the carbon atoms of the ring A moiety are optionally substituted by 1 to 3 R^{13} groups;

R^9 is $(C_1$-$C_8)$alkyl, $-(CR^{11}R^{12})_t(C_6$-$C_{10})$aryl or $-(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl, wherein t is independently 0, 1, 2, 3, 4, or 5, wherein said R^9 groups are substituted with 1 to 3 groups independently selected from $-(CR^{11}R^{12})_qNR^{10}R^{11}$, $-(CR^{11}R^{12})_qNR^{10}(C_1$-$C_6)$alkanoyl,

$-(CR^{11}R^{12})_qO(CR^{11}R^{12})_rR^{10}$, and $-(CR^{11}R^{12})_qR^{10}$; and wherein the heterocyclyl, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R^{13} groups;

R^{9a} and R^{10} are independently H or $(C_1\text{-}C_8)$alkyl;

R^{11} and R^{12} are independently H, $(C_1\text{-}C_8)$alkyl, hydroxy, or $(C_1\text{-}C_6)$alkoxy;

R^{10a} is selected from H, $(C_1\text{-}C_8)$alkyl, $-(C=O)-R^{14}$, $-SO_2NR^{15}R^{16}$, or $-S(O)_j(C_1\text{-}C_6)$alkyl;

Each R^{13} and R^{13a} are independently selected from the group consisting of halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_{10})$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, $-O-(CR^{11}R^{12})_k-O-(CR^{11}R^{12})_n-$, $-(C=O)-R^{14}$, $-(C=O)-O-R^{15}$, $-O-(C=O)-R^{15}$, $-NR^{15}(C=O)-R^{16}$, $-NR^{15}(C=O)-O-R^{16}$, $-(C=O)-NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-NR^{15}OR^{16}$, $-SO_2NR^{15}R^{16}$, $-S(O)_j(C_1\text{-}C_6)$alkyl, $-O-SO_2-R^{14}$, $-NR^{15}-SO_2-R^{16}$, $R^{15}-(CR^{11}R^{12})_t(C_6\text{-}C_{10}$ aryl), $-(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl, $-(CR^{11}R^{12})_q(C=O)(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl, $-(CR^{11}R^{12})_q(C=O)(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl, $-(CR^{11}R^{12})_tO(CR^{11}R^{12})_q(C_6\text{-}C_{10})$aryl, $-(CR^{11}R^{12})_tO(CR^{11}R^{12})_q$(4-10)-membered heterocyclyl, $-(CR^{11}R^{12})_qSO_2(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl, and $-(CR^{11}R^{12})_qSO_2(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl; 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{13} and R^{13a} groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^{13} and R^{13a} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^{15}$, $-(C=O)-R^{15}$, $-(C=O)-O-R^{15}$, $-O-(C=O)-R^{15}$, $-NR^{15}(C=O)-R^{16}$, $-(C=O)-NR^{15}R^{16}$, $-NR^{15}R^{16}$, $-NR^{15}OR^{16}$, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, $-(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl, and $-(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl;

each R^{14}, R^{15}, and R^{16} is independently selected from H, $(C_1\text{-}C_6)$alkyl, $-(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl, and $-(CR^{11}R^{12})_t$(4-10)-membered heterocyclyl; 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R^{14}, R^{15} and R^{16} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, $-NR^{11}R^{12}$, trifluoromethyl, trifluoromethoxy, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, hydroxy, and $(C_1\text{-}C_6)$ alkoxy;

R^{17} is H, $(C_1\text{-}C_8)$alkyl, $-O-(C_1\text{-}C_8)$alkyl, halo, CN, OH, CF_3, or $-O-CF_3$;

and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH (methine) group which is not attached to a halo, SO or SO_2 group or to a N, O or S atom optionally bears on said group a substituent selected from hydroxy, halo, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, $-NH_2$, $-NH(C_1\text{-}C_8)$alkyl, and $-N((C_1\text{-}C_8)alkyl)_2$.

2. The compound according to claim 1 wherein R^3 is

A) 

.

3. The compound according to claim 1 wherein R^3 is

B) 

4. The compound according to claim 1 wherein R^3 is

C) 

5. The compound according to claim 1 wherein R^3 is

D) 

6. The compound according to claim 1 wherein ring Q is selected from the group consisting of



7. The compound according to claim 1 wherein R^1 is H, halo, $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$alkoxy, CF_3, -O-CF_3, -O-SO_2-$(C_1\text{-}C_8)$alkyl, -O-SO_2-$(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl, or -$(CR^{11}R^{12})_t(C_6\text{-}C_{10})$aryl-O-, wherein the ring carbon atoms of R^1 are optionally substituted by 1 to 3 R^{13} groups.

8. The compound according to claim 1 wherein R^2 is H, phenyl,





, and .

9. The compound according to claim 1 wherein said  is selected from the group consisting of:



, and .

10. The compound according to claim 1 wherein said  is selected from the group consisting of:



and

11. The compound according to claim 1 wherein said  is selected from the group consisting of:



12. The compound according to claim 1 wherein R^4 is $-CH_2-O-$, $-CH_2-O-CH_2-$, $-CH_2-CH_2-O-$, $-CH=CH-CH_2-O-$, or $-CH_2-CH_2-CH_2-O-$.

13. The compound according to claim 1 wherein R^4 is $-(CH_2)_n-$; wherein n is independently 0, 1, 2, or 3.

14. The compound according to claim 1 wherein R^5 is a bond or $-(CR^{11}R^{12})_m-Z-(CR^{11}R^{12})_s$; wherein Z is -O-, $-NR^{10a}-$, or $-S(O)_j-$; wherein each m and s are independently 0, 1, 2, or 3; and wherein j is 0, 1, or 2.

15. The compound according to claim 1 wherein R^5 is a bond, -O-, $-CH_2-$, $-C(CH_3)H-$, -C(OH)H-, or $-C(O-(C_1-C_8)alkyl)H-$.

16. The compound according to claim 1 wherein R^6 is $-(C=O)-OH$.

17. The compound according to claim 1 wherein each R^7 and R^8 is independently H, (C_1-C_8)alkyl, or (C_1-C_8)alkoxy.

18. The compound according to claim 1 wherein each R^7 and R^8 are taken together with the carbon to which they are attached to form a (3-7)-membered heterocyclyl.

19. The compound according to claim 2 wherein said $-Ar^1-Ar^2-$ is selected from the group consisting of:



and ;

wherein the ring carbon atoms of each of Ar^1 and Ar^2 are optionally substituted by 1 to 3 R^{13} groups selected from the group consisting of halo, (C_1-C_8)alkyl, and (C_1-C_8)alkoxy.

20. The compound according to claim 2 wherein said $-Ar^1-Ar^2-$ is selected from the group consisting of:



21. The compound according to claim 2 selected from the group consisting of:

selected from the group consisting of

1-({3'-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1,1'-biphenyl-3-yl}oxy)cyclobutanecarboxylic acid (Example A-4);

2-({3'-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1,1'-biphenyl-3-yl}oxy)butanoic acid (Example A-5);

2-(3-{6-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}phenoxy)butanoic acid (Example A-6);

1-(3-{6-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}phenoxy)cyclobutanecarboxylic acid (Example A-7);

1-[(3'-{[2-(3-fluorophenyl)-5-methyl-1, 3-oxazol-4-yl]methoxy}biphenyl-3-yl)oxy]cyclobutanecarboxylic acid (Example A-11);

1-({3'-[3-(5-methyl-2-phenyl-1, 3-oxazol-4-yl)propoxy]biphenyl-3-yl}oxy)cyclobutanecarboxylic acid (Example A-12);

1-[(3'-{[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy}biphenyl-3-yl)oxy]cyclobutanecarboxylic acid (Example A-17);

2-[(3'-{2-[2-(3-Fluorophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}biphenyl-3-yl)oxy]-2-methylpropanoic acid (Example A-21);

2-methyl-2-({3'-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]biphenyl-3-yl}oxy)propanoic acid (Example A-24);

2-ethoxy-3-{3'-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]biphenyl-3-yl}propanoic acid (Example A-28);

and a pharmaceutically acceptable salt thereof.

22. The compound according to claim 3 wherein $-R^4-Y-Y''-$ is $-(CR^{11}R^{12})_n-O-(CR^{11}R^{12})_n-(C=O)-NR^{10}-$ or $-(CR^{11}R^{12})_n-NR^{10}-(C=O)-O-$.

23. The compound according to claim 3 wherein Y is -(C=O)- or $-SO_2-$, Y" is NR^{10}, and p is 1.

24. The compound according to claim 3 wherein each of R^{11} and R^{12} are independently H and Ar^3 is phenyl.

25. The compound according to claim 3 selected from the group consisting of

2-Methyl-2-{3-[({[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl}amino)methyl]phenoxy}propanoic acid (Example B-5);

2-methyl-2-{3-[({[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]carbonyl}amino)methyl]phenoxy}propanoic acid (Example B-6);

2-methyl-2-{4-[({[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]carbonyl}amino)methyl]phenoxy}propanoic acid (Example B-7);

2-{3-fluoro-4-[({[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl}amino)methyl]phenoxy}-2-methylpropanoic acid (Example B-9);

2-{3-[({[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl}amino)methyl]phenoxy}butanoic acid (Example B-13);

2-{3-[({[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]carbonyl}amino)methyl]phenoxy}butanoic acid (Example B-14);

1-{3-[({[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl}amino)methyl]phenoxy}cyclobutanecarboxylic acid (Example B-15);

2-methyl-2-(3-{[({[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]amino}carbonyl)oxy]methyl}phenoxy)propanoic acid (Example B-21);

2-ethoxy-3-{3-[({[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]carbonyl}amino)methyl]phenyl}propanoic acid (Example B-23);

2-ethoxy-3-{3-[({[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]carbonyl}amino)methyl]phenyl}propanoic acid (Example B-24);

and the pharmaceutically acceptable salts thereof.

26. The compound according to claim 4 wherein ring A is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

27. The compound according to claim 4 wherein ring A is selected from the group consisting of



wherein --- is an optional double bond.

28. The compound according to claim 4 wherein ring A is selected from the group consisting of



wherein --- is an optional double bond.

29. The compound according to claim 4 wherein ring A is selected from the group consisting of



wherein --- is an optional double bond.

30. The compound according to claim 4 wherein Ar^4 is phenyl, naphthyl, pyridinyl, pyrimidinyl, or pyrazinyl.

31. The compound according to claim 4 selected from the group consisting of

1-{4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propoxy]benzyl}cyclobutanecarboxylic acid (Example C-16);

1-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}cyclobutanecarboxylic acid (Example C-19);

2-({6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl}methyl)tetrahydrofuran-2-carboxylic acid (Example C-48);

2-({5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}methyl)tetrahydrofuran-2-carboxylic acid (Example C-49);

2-({6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl}methyl)tetrahydro-2*H*-pyran-2-carboxylic acid (Example C-56);

2-[(6-{2-[2-(3-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}pyridin-3-yl)methyl]tetrahydrofuran-2-carboxylic acid (Example C-59);

2-[(6-{2-[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}pyridin-3-yl)methyl]tetrahydrofuran-2-carboxylic acid (Example C-62);

2-{5-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyrazin-2-ylmethyl}-tetrahydro-furan-2-carboxylic acid (Example C-77);

-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}tetrahydrofuran-2-carboxylic acid (Example C-78);

2-{6-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-naphthalen-2-ylmethyl}-tetrahydro-furan-2-carboxylic acid (Example C-91);

and the pharmaceutically acceptable salts thereof.

32. The compound according to claim 5 having a formula:



; or



33. The compound according to claim 31 wherein R^9 is methyl, ethyl, or benzyl.

34. The compound according to claim 31 wherein R^{17} is H.

35. The compound according to claim 31 selected from the group consisting of
2-ethoxy-3-{6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl}propanoic acid (Example D-1);
2-methoxy-3-(6-{2-[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]ethoxy}pyridin-3-yl)propanoic acid (Example D-3);
2-methoxy-3-{6-[2-(4-phenoxyphenyl)ethoxy]pyridin-3-yl}propanoic acid (Example D-13);
2-ethoxy-3-[6-(2-{4-[(phenylsulfonyl)oxy]phenyl}ethoxy)pyridin-3-yl]propanoic acid (Example D-17);
2-Ethoxy-3-{5-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-2-yl}-propionic acid (Example D-23);
2-Methoxy-2-methyl-3-{6-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propoxy]-pyridin-3-yl}-propionic acid (Example D-27);
2-Methoxy-2-methyl-3-{5-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-2-yl}-propionic acid (Example D-29);
3-(6-{2-[2-(4-Chloro-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-pyridin-3-yl)-2-methoxy-2-methyl-propionic acid (Example D-30);
2-Methoxy-2-methyl-3-{6-[2-(5-methyl-2-phenyl oxazol-4-yl)-ethoxy]-pyridin-3-yl}-propionic acid (Example D-35);
2-Methoxy-3-(6-{2-[2-(3-methoxy-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-pyridin-3-yl)-2-methyl-propionic acid (Example D-43);
and the pharmaceutically acceptable salts thereof.

36. A method of treating non-insulin dependent diabetes mellitus in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

37. The method according to claim 36 wherein said mammal has an impaired glucose tolerance.

38. A method of treating polycystic ovarian syndrome in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

39. A method of treating polycystic obesity in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

40. A method of reducing body weight in an obese mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

41. A method of treating hyperglycemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

42. A method of treating hyperlipidemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

43. A method of treating hypercholesteremia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

44. A method of treating atherosclerosis in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

45. A method of treating hypertriglyceridemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

46. A method of treating hyperinsulinemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

47. A method of treating a patient suffering from abnormal insulin and/or evidence of glucose disorders associated with circulating glucocorticoids, growth hormone, catecholamines, glucagon, or parathyroid hormone, comprising administering to said patient a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

48. A method of treating insulin resistance syndrome in humans comprising administering to a patient in need of treatment a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

49. A method of treating PPAR-related disorders in humans comprising administering to a patient in need of treatment a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

50. A method of modulating PPAR activity in a mammal, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

51. A method of lowering blood glucose in a mammal, comprising administering to a mammal an amount of an alpha substituted carboxylic acid compound according to claim 1 therapeutically effective to lower blood glucose levels.

52. A method of modulating fat cell differentiation in a mammal, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

53. A method of modulating processes mediated by PPAR in a mammal, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

54. A method of increasing insulin sensitivity in mammals, comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

55. A method of treating metabolic syndromes selected from the group consisting of galactosemia, maple syrup urine disease, phenylketonuria, hypersarcosinemia, thymine uraciluria, sulfinuria, isovaleric acidemia, saccharopinuria, 4-hydroxybutyric aciduria, glucose-6-phosphate dehydrogenase deficiency, and pyruvate dehydrogenase deficiency comprising administering to a mammal a therapeutically effective amount of an alpha substituted carboxylic acid compound according to claim 1.

56. A composition comprising at least one compound of Formula (I) according to claim 1 and a pharmaceutically acceptable carrier thereof.